Neovascular age-related macular degeneration (nAMD)
Conditions
Interventions
Intervention group:Injection of Aflibercept
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. nAMD with type I CNV was diagnosed by OCT and FFA, and active CNV was confirmed by OCTA; 3. At least 4 intravitreal injections of leizumab or compacept were received in the 6 months before dressing change, and IRF or SRF remained persistent under OCT after two consecutive injections; 4. BCVA is less than or equal to 73 letters; 5. Patients agree to participate in clinical trials and sign informed consent; 6. Patients were able to participate in the treatment and the 12 month follow-up period.
Exclusion criteria
Exclusion criteria: 1. The patient had contraindications to abercept, including eye and periocular infection, active intraocular inflammation, etc.; 2. There are other eye diseases that may affect the patient's vision; 3. History of vitreoretinal surgery, including scleral buckling; 4. History of cataract surgery within 90 days; 5. To investigate macular central structural damage in the eyes that may hinder BCVA improvement, including retinal pigment epithelial atrophy, subretinal fibrosis or scarring; Those who were assessed as mature CNV by OCTA examination before enrollment; 6. Intraocular pressure of study eye >=25 mmHg; 7. High myopia prior to refractive surgery or cataract surgery; 8. Pregnant or lactating patients; 9. On hormonal or immunosuppressive therapy; 10. Patients with active infections and autoimmune diseases, including hepatitis B, hepatitis C, systemic lupus erythematosus, etc.; 11. Known sensitivities to possible therapeutic agents (patients allergic to appercept or excipients); 12. Patients with incomplete functions of heart, liver, kidney and other important organs; 13. Concurrent treatment with experimental drugs or devices in other clinical studies; 14. The investigator considered that the patient had other conditions that were not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity;intraocular pressure;optical coherence tomography;optical coherence tomography angiography;fundus angiography;number of Aflibercept injections;adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang Meixia
West China Hospital of Sichuan University
Outcome results
None listed